Question 1

Clinical Significance

Accepted Answer

Determines tumor responsiveness to targeted therapies like Cetuximab or Panitumumab. Prevents the use of ineffective treatments in patients with mutations. Optimizes the clinical outcome by personalizing the oncology care plan.

Question 2

Target Groups

Accepted Answer

Patients diagnosed with metastatic colorectal cancer (mCRC). Patients being considered for anti-EGFR targeted therapy. Cases where initial chemotherapy has failed and new options are needed.

Question 3

Interpretation of Results

Accepted Answer

Wild-Type: Indicates the patient is likely to benefit from anti-EGFR therapy. Mutant: Indicates the therapy is unlikely to work, guiding the doctor to other options.

RAS Mutation Test for Colon Cancer - KRAS and NRAS Mutation Testing for Colorectal Cancer